FI963393L - Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä - Google Patents

Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä Download PDF

Info

Publication number
FI963393L
FI963393L FI963393A FI963393A FI963393L FI 963393 L FI963393 L FI 963393L FI 963393 A FI963393 A FI 963393A FI 963393 A FI963393 A FI 963393A FI 963393 L FI963393 L FI 963393L
Authority
FI
Finland
Prior art keywords
gene expression
cancer conditions
determining cancer
mage gene
mage
Prior art date
Application number
FI963393A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963393A7 (fi
FI963393A0 (fi
Inventor
Plaen Etienne De
Thierry Boon-Falleur
Bernard Lethe
Jean-Pierre Szikora
Smet Charles De
Patrick Chomez
Beatrice Gaugler
Den Eynde Benoit Van
Francis Brasseur
Jean-Jacques Patard
P Weynants
M Marchand
Der Bruggen Pierre Van
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/204,727 external-priority patent/US5512437A/en
Priority claimed from US08/209,172 external-priority patent/US5763165A/en
Priority claimed from US08/299,849 external-priority patent/US5612201A/en
Priority claimed from US08/346,774 external-priority patent/US5512444A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI963393A7 publication Critical patent/FI963393A7/fi
Publication of FI963393A0 publication Critical patent/FI963393A0/fi
Publication of FI963393L publication Critical patent/FI963393L/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
FI963393A 1994-03-01 1995-02-23 Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä FI963393L (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/204,727 US5512437A (en) 1994-03-01 1994-03-01 Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US08/209,172 US5763165A (en) 1994-03-10 1994-03-10 Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US08/299,849 US5612201A (en) 1991-05-23 1994-09-01 Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
US08/346,774 US5512444A (en) 1994-03-01 1994-11-30 Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
PCT/US1995/002203 WO1995023874A1 (fr) 1994-03-01 1995-02-23 Determination d'etats cancereux par l'expression de genes mage

Publications (3)

Publication Number Publication Date
FI963393A7 FI963393A7 (fi) 1996-08-30
FI963393A0 FI963393A0 (fi) 1996-08-30
FI963393L true FI963393L (fi) 1996-08-30

Family

ID=27498545

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963393A FI963393L (fi) 1994-03-01 1995-02-23 Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä

Country Status (11)

Country Link
EP (1) EP0871765B1 (fr)
JP (1) JPH09509832A (fr)
KR (1) KR100316209B1 (fr)
AT (1) ATE209690T1 (fr)
AU (1) AU698310B2 (fr)
CA (1) CA2184482A1 (fr)
DE (1) DE69524264T2 (fr)
FI (1) FI963393L (fr)
NO (1) NO963589L (fr)
NZ (1) NZ282536A (fr)
WO (1) WO1995023874A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221593B1 (en) * 1996-10-03 2001-04-24 Ludwig Institute For Cancer Research Method for determining cancer by determining expression of MAGE-10
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
WO1998046788A2 (fr) 1997-04-11 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Nouvelles amorces et procedes de detection des cellules tumorales disseminees
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
EP0996857B1 (fr) * 1997-07-17 2009-09-09 Ludwig Institute For Cancer Research Acides nucleiques et polypeptides associes au cancer
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
AU764911B2 (en) * 1998-08-31 2003-09-04 Agensys, Inc. PHELIX: a testis-specific protein expressed in cancer
US6733998B1 (en) * 1998-12-07 2004-05-11 Sloan-Kettering Institute For Cancer Research Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
US6475794B1 (en) * 1999-10-08 2002-11-05 The Johns Hopkins University Converting diploidy to haploidy for genetic diagnosis
CA2443968A1 (fr) 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnostic et traitement du cancer
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2016094309A1 (fr) 2014-12-10 2016-06-16 Myosotis Inhibition de la signalisation de tnf en immunothérapie du cancer
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
CN111836635A (zh) 2018-01-26 2020-10-27 剑桥企业有限公司 肽交换蛋白
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
US12329816B2 (en) 2018-08-24 2025-06-17 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
US20220267409A1 (en) 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137231A1 (fr) 2019-12-31 2021-07-08 Kahr Medical Ltd. Procédés de culture de lymphocytes t avec un polypeptide de fusion 4-1bbl et leurs utilisations
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
US20240317871A1 (en) 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (fr) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anticorps de récepteur du récepteur anti-activine 1c (alk-7)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Also Published As

Publication number Publication date
EP0871765A1 (fr) 1998-10-21
FI963393A7 (fi) 1996-08-30
AU698310B2 (en) 1998-10-29
WO1995023874A1 (fr) 1995-09-08
FI963393A0 (fi) 1996-08-30
EP0871765B1 (fr) 2001-11-28
NZ282536A (en) 1998-07-28
JPH09509832A (ja) 1997-10-07
DE69524264D1 (de) 2002-01-10
NO963589L (no) 1996-10-31
ATE209690T1 (de) 2001-12-15
EP0871765A4 (fr) 1999-08-11
KR970701790A (ko) 1997-04-12
DE69524264T2 (de) 2002-07-18
KR100316209B1 (ko) 2002-06-26
CA2184482A1 (fr) 1995-09-08
NO963589D0 (no) 1996-08-28
AU1968295A (en) 1995-09-18

Similar Documents

Publication Publication Date Title
FI963393A7 (fi) Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä
TR199501724A2 (tr) Sizdirmazlik saglayici düzen.
NO981283D0 (no) Låseskjöt
FI962980L (fi) Muunnetut oligonukleotidit
FI972066A0 (fi) Uusi kasvainten suppressorigeeni HIC-1
DE69630414D1 (de) 5B4T-Kodierungsschema
DK0967286T3 (da) Leucinaminopeptodase-gen
EP0904279A4 (fr) Dpc4, nouveau gene suppresseur de tumeur
NO962596D0 (no) Nytt tumorsupressorgen
IT1284513B1 (it) Impianto di rivestimento per foglie
BR9610194A (pt) Aminouracilas substituídas
KR970000761U (ko) 앨범 내지
FI1943U1 (fi) Bomsystem till skogmaskin
KR960032276U (ko) 라디에이터
UA10736A (uk) Ћ†љ
KR960032285U (ko) 라디에이터용 방열기
FI950104A0 (fi) Isolerad yttervaegg till timmerhus
FI951869A0 (fi) Torknings foerfarande foer malt
FI2455U1 (fi) Lämpöpatteri
IT239009Y1 (it) Radiatore
KR970044842U (ko) 라디에이터
KR970044833U (ko) 라디에이터
KR960032287U (ko) 라디에이터
FI2002U1 (fi) Haollare till spoestaell
FI2187U1 (fi) Hoerndetalj till plaottlaoda